This study will aim to assess how effective the next generation of BTX-A-HAC (BTX-A-HAC NG) with an injectable liquid formulation is for improving the appearance of lines (wrinkles) between the eyebrows (glabellar area) The primary study objective is to demonstrate the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX A HAC; hereafter referre...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase III, multicentre study assesssing the long term safety and and efficay of repeated treatments with Dysport in the treatment of arm spasticity in adult patients with hemiparesis The primary study objective is to assess the long term safety of Dysport in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, placebo controlled clinical trial to assess efficacy and safety of one dose of Dysport solution in the treatment of upper limb spasticity in adults after stroke To assess the efficacy of Dysport Solution 1000 U compared to placebo in reducing the upper limb muscle tone (using the Modified Ashworth Scale (MAS)) in adult subjects with upper limb spastic hemipar...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study looking at DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination caused by spinal cord injury or multiple sclerosis • To assess the efficacy of two Dysport® doses (600 units (U) and 800 U), compared to placebo in reducing UI from Baseline to Week 6 following the first investigational medicinal product (IMP) adminis...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days Eficacia y seguridad de lanreotide Autogel® 120 mg administrado cada 14 días en tumores neuroendocrinos de intestino medio o pancreáticos que han progresado radiológicamente durante el tratamiento anterior con lanreotide Autogel® 120 mg administrado cada 28 días To assess progression free survival (PFS) when treated with lanreotide Autogel® 120 mg administered every 14 days based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.0, and according to...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase 3, blinded, multicentre study assessing efficacy and safety of Dysport for treatment of upper limb spasticity (altered skeletal muscle performance) in children The primary study objective is to assess the efficacy of two doses of Dysport (8 U/kg and 16 U/kg) compared to Dysport 2 U/kg used in the treatment of upper limb spasticity in children with CP followi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosis • To assess the efficacy of two Dysport® doses (600 units (U) and 800 U), compared to placebo in reducing UI from Baseline to Week 6 following the first investigational medicinal product (IMP) adminis...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The purpose of this clinical study is to assess safety and efficacy of different doses of Dysport® RU (RU= Ready to Use), a new formulation of a drug called Dysport®, which is used for the improvement in the appearance of glabellar lines (lines that appear on the forehead between the eyebrows). Additionally, the study will aim to establish the dose of Dysport® RU, which is equivalent in terms of safety and efficacy to the optimal dose of 50 U of Dysport® The primary objective is to assess the dose response versus placebo of a single treatment with Dysport RU used for the improvement in the appearance of moderate to severe glabellar lines at maximum fr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase III, multicentre study assessing the efficacy and safety of Dysport compared to a Placebo for the treatment of upper limb spasticity in adult patients with hemiparesis The primary study objective is to assess the efficacy of Dysport compared to placebo in reducing upper limb muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic br...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The aim of the study is to assess the efficacy and safety of intra - detrusor injections of Dysport versus placebo in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis The primary study objective is to assess the efficacy of a single dose of Dysport (750 U) compared to placebo for the improvement in the daily incontinence episode frequency (IEF) for each administrat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune